Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zorubicin
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Zorubicin is a benzoylhydrazone derivative of the anthracycline antineoplastic antibiotic daunorubicin. It exerts its anticancer effects by intercalating into DNA, interacting with and inhibiting topoisomerase II, and inhibiting DNA polymerases. These actions collectively disrupt DNA replication, repair, and the synthesis of RNA and proteins, leading to cell death in various cancer types.
- Brand names
- RubidazonRubidazoneZorubicine
- Other names
- benzoyl hydrazone daunorubicindaunorubicin benzoylhydrazone hydrochloride
02
Targets
DNADNA polymerase familyTOP2A (DNA topoisomerase II)RNAP (Bacterial dna-dependent RNA polymerase)
Beyond the preview
Go deeper on Zorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zorubicin.